160 related articles for article (PubMed ID: 11087569)
1. Computational studies on HIV-1 protease inhibitors: influence of calculated inhibitor-enzyme binding affinities on the statistical quality of 3D-QSAR CoMFA models.
Jayatilleke PR; Nair AC; Zauhar R; Welsh WJ
J Med Chem; 2000 Nov; 43(23):4446-51. PubMed ID: 11087569
[TBL] [Abstract][Full Text] [Related]
2. Computational studies on tetrahydropyrimidine-2-one HIV-1 protease inhibitors: improving three-dimensional quantitative structure-activity relationship comparative molecular field analysis models by inclusion of calculated inhibitor- and receptor-based properties.
Nair AC; Jayatilleke P; Wang X; Miertus S; Welsh WJ
J Med Chem; 2002 Feb; 45(4):973-83. PubMed ID: 11831910
[TBL] [Abstract][Full Text] [Related]
3. Molecular docking and 3D-QSAR studies of HIV-1 protease inhibitors.
Khedkar VM; Ambre PK; Verma J; Shaikh MS; Pissurlenkar RR; Coutinho EC
J Mol Model; 2010 Jul; 16(7):1251-68. PubMed ID: 20069323
[TBL] [Abstract][Full Text] [Related]
4. 3D-QSAR CoMFA/CoMSIA models based on theoretical active conformers of HOE/BAY-793 analogs derived from HIV-1 protease inhibitor complexes.
da Cunha EF; Sippl W; de Castro Ramalho T; Ceva Antunes OA; de Alencastro RB; Albuquerque MG
Eur J Med Chem; 2009 Nov; 44(11):4344-52. PubMed ID: 19616874
[TBL] [Abstract][Full Text] [Related]
5. Comparative molecular field analysis (CoMFA), topomer CoMFA, and hologram QSAR studies on a series of novel HIV-1 protease inhibitors.
Heidari A; Fatemi MH
Chem Biol Drug Des; 2017 Jun; 89(6):918-931. PubMed ID: 27933723
[TBL] [Abstract][Full Text] [Related]
6. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies.
Hou T; Zhu L; Chen L; Xu X
J Chem Inf Comput Sci; 2003; 43(1):273-87. PubMed ID: 12546563
[TBL] [Abstract][Full Text] [Related]
7. Three-dimensional QSAR of human immunodeficiency virus (I) protease inhibitors. 1. A CoMFA study employing experimentally-determined alignment rules.
Waller CL; Oprea TI; Giolitti A; Marshall GR
J Med Chem; 1993 Dec; 36(26):4152-60. PubMed ID: 8277496
[TBL] [Abstract][Full Text] [Related]
8. Comparative molecular field analysis of a series of inhibitors of HIV-1 protease.
Ferreira LG; Leitão A; Montanari CA; Andricopulo AD
Med Chem; 2011 Mar; 7(2):71-9. PubMed ID: 21222610
[TBL] [Abstract][Full Text] [Related]
9. 3D-QSAR of human immunodeficiency virus (I) protease inhibitors. III. Interpretation of CoMFA results.
Opera TI; Waller CL; Marshall GR
Drug Des Discov; 1994 Jul; 12(1):29-51. PubMed ID: 7578806
[TBL] [Abstract][Full Text] [Related]
10. Multiple receptor conformation docking and dock pose clustering as tool for CoMFA and CoMSIA analysis - a case study on HIV-1 protease inhibitors.
Sivan SK; Manga V
J Mol Model; 2012 Feb; 18(2):569-82. PubMed ID: 21547550
[TBL] [Abstract][Full Text] [Related]
11. Correlation between the predicted and the observed biological activity of the symmetric and nonsymmetric cyclic urea derivatives used as HIV-1 protease inhibitors. A 3D-QSAR-CoMFA method for new antiviral drug design.
Avram S; Svab I; Bologa C; Flonta ML
J Cell Mol Med; 2003; 7(3):287-96. PubMed ID: 14594553
[TBL] [Abstract][Full Text] [Related]
12. Molecular dynamics simulations of 14 HIV protease mutants in complexes with indinavir.
Chen X; Weber IT; Harrison RW
J Mol Model; 2004 Dec; 10(5-6):373-81. PubMed ID: 15597206
[TBL] [Abstract][Full Text] [Related]
13. Integrating Multiple Receptor Conformation Docking and Multi Dimensional QSAR for Enhancing Accuracy of Binding Affinity Prediction.
Radhika V; Jaraf HA; Kanth SS; Vijjulatha M
Curr Comput Aided Drug Des; 2017; 13(2):127-142. PubMed ID: 28103770
[TBL] [Abstract][Full Text] [Related]
14. Revealing interaction mode between HIV-1 protease and mannitol analog inhibitor.
Yan GW; Chen Y; Li Y; Chen HF
Chem Biol Drug Des; 2012 Jun; 79(6):916-25. PubMed ID: 22296911
[TBL] [Abstract][Full Text] [Related]
15. 3D-QSAR studies on chromone derivatives as HIV-1 protease inhibitors: application of molecular field analysis.
Nunthanavanit P; Anthony NG; Johnston BF; Mackay SP; Ungwitayatorn J
Arch Pharm (Weinheim); 2008 Jun; 341(6):357-64. PubMed ID: 18442018
[TBL] [Abstract][Full Text] [Related]
16. Structure-based QSAR analysis of a set of 4-hydroxy-5,6-dihydropyrones as inhibitors of HIV-1 protease: an application of the receptor-dependent (RD) 4D-QSAR formalism.
Santos-Filho OA; Hopfinger AJ
J Chem Inf Model; 2006; 46(1):345-54. PubMed ID: 16426069
[TBL] [Abstract][Full Text] [Related]
17. Three-dimensional quantitative structure-property relationship (3D-QSPR) models for prediction of thermodynamic properties of polychlorinated biphenyls (PCBs): enthalpies of fusion and their application to estimates of enthalpies of sublimation and aqueous solubilities.
Puri S; Chickos JS; Welsh WJ
J Chem Inf Comput Sci; 2003; 43(1):55-62. PubMed ID: 12546538
[TBL] [Abstract][Full Text] [Related]
18. Efficiency of a second-generation HIV-1 protease inhibitor studied by molecular dynamics and absolute binding free energy calculations.
Lepsík M; Kríz Z; Havlas Z
Proteins; 2004 Nov; 57(2):279-93. PubMed ID: 15340915
[TBL] [Abstract][Full Text] [Related]
19. CoMFA and CoMSIA 3D QSAR and docking studies on conformationally-restrained cinnamoyl HIV-1 integrase inhibitors: exploration of a binding mode at the active site.
Buolamwini JK; Assefa H
J Med Chem; 2002 Feb; 45(4):841-52. PubMed ID: 11831895
[TBL] [Abstract][Full Text] [Related]
20. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
Muzammil S; Ross P; Freire E
Biochemistry; 2003 Jan; 42(3):631-8. PubMed ID: 12534275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
